RECRUITING

Losartan in Prevention of Radiation-Induced Heart Failure

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is being done to see if losartan affects the chances of developing radiation-induced heart failure in patients who are receiving radiation therapy as part of standard of care treatment for breast cancer. The interventions involved in this study are: * Losartan * Radiation Therapy (standard of care)

Official Title

The Role of Losartan in the Prevention of Early Structural Changes Associated With Radiation-Induced Heart Failure

Quick Facts

Study Start:2024-01-01
Study Completion:2024-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05607017

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Non-metastatic Breast Cancer patients who are scheduled to receive conventional left breast/chest wall RT inclusive of treatment to the internal mammary lymph nodes (IMNs)
  2. * Prior chemotherapy is permitted
  3. * Patients must have Left-sided Breast Cancer
  4. * Ability to understand and the willingness to sign a written informed consent document
  5. * No contraindication to MRI
  1. * Person who is pregnant or breastfeeding.
  2. * Patient unable to swallow oral medication.
  3. * Patients receiving any other investigational agent will not be excluded from study eligibility, unless the patient is already enrolled in an interventional study evaluating cardiac toxicity
  4. * Patients already receiving ACE/ARBs.
  5. * Patients with a history of allergic reactions to Losartan biosimilars.

Contacts and Locations

Study Contact

Rachel Jimenez, MD
CONTACT
617-726-8651
rbjimenez@partners.org

Principal Investigator

Rachel Jimenez, MD
PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital

Study Locations (Sites)

Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
United States

Collaborators and Investigators

Sponsor: Massachusetts General Hospital

  • Rachel Jimenez, MD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-01-01
Study Completion Date2024-12-01

Study Record Updates

Study Start Date2024-01-01
Study Completion Date2024-12-01

Terms related to this study

Keywords Provided by Researchers

  • Breast Cancer
  • Myocardial Fibrosis
  • Radiation-Induced Fibrosis

Additional Relevant MeSH Terms

  • Breast Cancer
  • Myocardial Fibrosis
  • Radiation-Induced Fibrosis